CVS Health clears 52-week high, shares react to GLP-1 expansion and analyst moves

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 16:15.

CVS Health Corp. (US1266501006) has marked a new 52-week high on the NYSE in recent sessions. The shares touched 102.78 US dollars, with analysts pointing to expanded GLP-1 programs and fresh price targets as key drivers according to Investing.com and BofA Securities.

What the recent high shows

According to Investing.com, CVS Health shares hit a 52-week peak of 102.78 dollars and recently traded around 102.76 dollars, representing a 53.3 percent gain over the past year. The stock is part of the S&P 500 healthcare cohort, alongside peers such as UnitedHealth and Humana.

Investing.com notes that CVS Health has distributed dividends for 56 consecutive years, underscoring a long dividend track record within the US healthcare sector. The platform’s InvestingPro tool currently views the stock as undervalued versus its fair value estimate, though this represents third-party analysis rather than company guidance.

Analysts lift their CVS view

A mid-June report cited by Yahoo Finance and The New York Times coverage highlights that Mizuho raised its CVS Health price target from 110 to 115 dollars on June 8, 2026, while reiterating an Outperform rating. The bank expects a more predictable policy backdrop, reducing regulatory surprises for US managed-care names.

More recently, BofA Securities lifted its price target for CVS Health to 110 dollars and maintained a Buy rating, explicitly flagging the company’s GLP-1 program expansion as a positive earnings driver. Cantor Fitzgerald reaffirmed an Overweight stance with a 100 dollar target, citing the potential of new managed-care agreements to support earnings over the next cycles.

GLP-1 programs as a growth angle

Investing.com reports that CVS Health has expanded support for GLP-1 medications across thousands of US pharmacy locations, MinuteClinic sites and its digital platform. The offering includes a Medicare Bridge initiative priced at around 50 dollars per month and commercial options starting near 25 dollars for eligible patients.

The company is preparing to engage with the Centers for Medicare & Medicaid Services via a Medicare GLP-1 Bridge program from July 1, 2026, aiming to improve access to selected GLP-1 therapies at lower out-of-pocket cost for eligible beneficiaries. CVS has also adjusted its commercial formularies, for example by prioritizing specific GLP-1 brands in obesity and diabetes treatment pathways.

Regulatory scrutiny and Medicare Advantage

A June 11, 2026 New York Times report, summarized by Yahoo Finance, cited Department of Health and Human Services documents indicating that Medicare Advantage insurers including CVS Health, UnitedHealth and Humana denied around 13 percent of skilled nursing facility admission requests to contain costs. For patients already residing in nursing homes, the denial rate in the documents reached roughly 40 percent.

CVS spokesperson David Whitrap told The New York Times that the company reviews authorization requests quickly and offers a defined appeals process, emphasizing that the stated priority is timely patient access to necessary care. The discussion illustrates the regulatory and reputational backdrop in which CVS’s managed-care and Aetna businesses operate.

What the company sells

CVS Health’s business spans retail pharmacy chains, pharmacy benefit management under the Caremark brand and health insurance via Aetna, with additional primary and urgent care services through MinuteClinic. The GLP-1 support initiatives tie together these segments by combining insurance coverage decisions, pharmacy dispensing and digital patient support programs.

Where the stock trades today

The CVS Health shares (US1266501006) most recently traded on the NYSE at 102.76 US dollars on 2026-06-23, 15:30 New York time, according to Investing.com.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.